24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Startup: Confidential
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Pharmaceuticals
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
13:10
Israeli high-tech shows signs of recovery with $1.6 billion raised in 105 rounds in Q1 of 2024
13:02
After fleeing Iran and an illustrious career in Israeli intelligence, Sanaz Yashar raises $30M for cyber startup
12:00
Cyber startup Coro nets $100 million Series D to make enterprise-grade security accessible to all
11:16
Full list of Israeli high-tech funding rounds in 2024
More stories
Buzz
Most popular
Daily
Weekly
1
From Yemen to Iran: Israel's new $1 billion spy plane is a war game changer
2
Legendary Israeli investor strikes gold again with Astera Labs
3
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
4
Black Cube Moves into Larger, Fancier Headquarters
5
Jefferies CEO: “There is an influx of innovation here that makes Israel an important place for investors”
More news
Pharmaceuticals
20 stories about Pharmaceuticals
Teva Completes $47.5 Million Sale of Northern Israeli Plant to Private Equity Fund FIMI
02.05.19
|
Hezi Sternlicht
Teva is selling the plant following its 2017 plan to ameliorate its crippling debt by divesting non-core businesses and closing or selling many of its manufacturing plants
Can-Fite BioPharma Receives $1 Million From CKD Pharmaceuticals as Part of Expanded Agreement
16.04.19
|
CTech
Israel-based Can-Fite expanded its distribution agreement with the South Korean company in February, and is entitled to up to $5 million more in milestones
Can-Fite BioPharma to Raise $3.2 Million in Direct Offering
04.04.19
|
CTech
The NYSE and Tel Aviv-listed company develops small molecule drugs used in the treatment of liver and inflammatory diseases and cancer
Teva Makes Headway in European Copaxone Patent Case
01.04.19
|
Lilach Baumer
Generic 40 mg versions of the drugmaker's blockbuster drug for multiple sclerosis have been available in Europe since late 2017, but Teva is now making strides in court
Life Science Investment Firm Pontifax Raises $170 Million Fund
22.11.18
|
Meir Orbach
The firm’s new fund, its sixth, will focus on credit loans to pharmaceutical companies planning to go public
Biotech Company Polypid Raises $15 Million
07.11.18
|
Lilach Baumer
Israel-based Polypid develops encapsulating drug delivery technology that enables extended and localized release in the body
Former Teva Executives Raise $60 Million for Metabolic Disorders Venture
28.10.18
|
Lilach Baumer
The company’s pipeline of biologic and small molecule drug candidates was acquired from Teva
China’s CMS Medical Signs Multi-Million Dollar Deal With Israeli Pharma Company Can-Fite
07.08.18
|
Amarelle Wenkert
New York-listed Can-Fite develops small molecule drugs used in the treatment of liver and inflammatory diseases and cancer
Teva Trending Down Following Underwhelming Second Quarter Revenues
02.08.18
|
Dror Reich
On Thursday, the generic drugmaker announced revenues that fell slightly short of analyst consensus
Mylan Cuts Price of Generic Copaxone Offering by 60%
11.07.18
|
Lilach Baumer
Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
Oral Insulin Capsule Developer Oramed Raises $18 Million in Direct Offering
10.07.18
|
CTech
Jerusalem-headquartered Oramed intends to use the recent proceeds for research and development and for clinical trials
Teva to Relocate U.S. Headquarters to New Jersey
08.07.18
|
Lilach Baumer
In December, the Israeli drugmaker announced a far-reaching cost cutting plan to deal with its multi-billion debt
Cost-Cutting at CureTech Following Cancellation of Acquisition Deal with Insight
05.07.18
|
CTech
The deal was announced in March, but intended buyer InSight backed out
Goldman Sachs Sees 16% Upside in Teva Stock
26.06.18
|
Dror Reich
Following a meeting with Teva’s management, the bank's analysts reiterated their "buy" recommendation with a higher target price
Liver Treatment Company Galmed Looking to Raise $75 Million in Public Offering
20.06.18
|
Dror Reich
Galmed listed on Nasdaq in 2014. The company's stock jumped around 125% over the past two weeks following a successful study
MediWound’s Pineapple-Based Burn Treatment to Treat Mustard Gas Burns
31.05.18
|
Dror Reich
The Nasdaq-listed, Israeli based company received the FDA’s approval to expand the use of flagship burn treatment NexoBrid to those suffering from Sulfur Mustard injuries
At Swiss Pharma Company, Women’s Health Gets Personal
23.05.18
|
Lilach Baumer
Ferring Pharmaceuticals recently launched a personalized fertility treatment that supports its hormone therapy with a dosage calculation app
Berkshire Hathaway Solidified its Teva Position in 2018 First Quarter
16.05.18
|
Lilach Baumer
According to a Tuesday filing, Berkshire Hathaway more than doubled its Teva stake during the first quarter of 2018
Israel’s Life Sciences Industry Is Dominated by Small Scale Startups
14.05.18
|
Lilach Baumer
65% of all Israel-based life sciences companies employ 10 people or less, according to a new report
Building on Strong First Quarter, Teva Raises 2018 Outlook
03.05.18
|
Lilach Baumer and Dror Reich
The company reported a 10% decrease in revenues compared to 2017, largely due to North American Copaxone troubles, but beat analyst expectations
Previous Articles
More Articles
Please ensure Javascript is enabled for purposes of
website accessibility